MicroRNA‑381 regulates the growth of gastric cancer cell by targeting TWIST1

Yin,Yongling; Li,Xiaoyun; Guo,Zongquan; Zhou,Fuxiang

doi:10.3892/mmr.2019.10651

MicroRNA‑381 regulates the growth of gastric cancer cell by targeting TWIST1

Authors:
- Yongling Yin
- Xiaoyun Li
- Zongquan Guo
- Fuxiang Zhou
View Affiliations

Affiliations: Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China, Department of Internal Medicine‑Oncology, Affiliated People's Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia 010020, P.R. China, Digestive Department, Affiliated People's Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia 010020, P.R. China
Published online on: September 6, 2019 https://doi.org/10.3892/mmr.2019.10651
Pages: 4376-4382

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric cancer (GC) has one of the highest mortality rates among all types of cancer in the world. At present, an efficient treatment for GC remains elusive. Studies have demonstrated that microRNAs (miRs) are abnormally expressed in cancer, and that these serve important roles in the development and metastasis of various human tumors, including GC. It has been suggested that regulation of miRs may bring about new developments in GC therapy. miR‑381 has been reported to be downregulated in human cancer, and it regulates cancer cell growth in numerous types of cancer. The present study reports that miR‑381 was downregulated in GC cells, and upregulation of miR‑381 may inhibit GC cell growth, which may be attributed to the inhibition of cell proliferation and the promotion of apoptosis. Furthermore, Twist‑related protein 1 (TWIST1) was predicted and confirmed to be a direct target of miR‑381 by dual‑luciferase assay in GC. Upregulation of miR‑381 caused a decrease in the expression of TWIST1 at the mRNA and protein levels in GC cells. Taken together, the present study demonstrated that miR‑381 is downregulated in GC cells, and that miR‑381 may inhibit GC cell growth. Therefore, miR‑381 may serve as a novel target for the clinical treatment of GC in the future.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Karpińska-Kaczmarczyk K, Lewandowska M, Białek A, Ławniczak M and Urasińska E: Gastric hyperplastic polyps coexisting with early gastric cancers, adenoma and neuroendocrine cell hyperplasia. Pol J Pathol. 67:33–38. 2016. View Article : Google Scholar : PubMed/NCBI
3	Ushijima T and Sasako M: Focus on gastric cancer. Cancer Cell. 5:121–125. 2004. View Article : Google Scholar : PubMed/NCBI
4	Smith MG, Hold GL, Tahara E and El-Omar EM: Cellular and molecular aspects of gastric cancer. World J Gastroenterol. 12:2979–2990. 2006. View Article : Google Scholar : PubMed/NCBI
5	Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
6	Vilaseca Cabo A, Musquera Felip M, Ribal Caparros MJ and Alcaraz Asensio A: Metastasis of gastric carcinoma simulating a urothelial tumor. Case report and review of the literature. Arch Esp Urol. 66:885–889. 2013.(In Spanish). PubMed/NCBI
7	Compare D, Rocco A and Nardone G: Risk factors in gastric cancer. Eur Rev Med Pharmacol Sci. 14:302–308. 2010.PubMed/NCBI
8	Huang H, Han Y, Zhang C, Wu J, Feng J, Qu L and Shou C: HNRNPC as a candidate biomarker for chemoresistance in gastric cancer. Tumour Biol. 37:3527–3534. 2016. View Article : Google Scholar : PubMed/NCBI
9	Li Y, Gong J, Zhang Q, Lu Z, Gao J, Li Y, Cao Y and Shen L: Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer. Br J Cancer. 114:138–145. 2016. View Article : Google Scholar : PubMed/NCBI
10	Oue N, Aung PP, Mitani Y, Kuniyasu H, Nakayama H and Yasui W: Genes involved in invasion and metastasis of gastric cancer identified by array-based hybridization and serial analysis of gene expression. Oncology. 69 (Suppl 1):S17–S22. 2005. View Article : Google Scholar
11	Iorio MV and Croce CM: MicroRNAs in cancer: Small molecules with a huge impact. J Clin Oncol. 27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
12	Glud M, Rossing M, Hother C, Holst L, Hastrup N, Nielsen FC, Gniadecki R and Drzewiecki KT: Downregulation of miR-125b in metastatic cutaneous malignant melanoma. Melanoma Res. 20:479–484. 2010. View Article : Google Scholar : PubMed/NCBI
13	Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, et al: Relation between microRNA expression and progression and prognosis of gastric cancer: A microRNA expression analysis. Lancet Oncol. 11:136–146. 2010. View Article : Google Scholar : PubMed/NCBI
14	Croce C: Introduction to the role of microRNAs in cancer diagnosis, prognosis, and treatment. Cancer J. 18:213–214. 2012. View Article : Google Scholar : PubMed/NCBI
15	Holley CL and Topkara VK: An introduction to small non-coding RNAs: miRNA and snoRNA. Cardiovasc Drugs Ther. 25:151–159. 2011. View Article : Google Scholar : PubMed/NCBI
16	Iorio MV and Croce CM: microRNA involvement in human cancer. Carcinogenesis. 33:1126–1133. 2012. View Article : Google Scholar : PubMed/NCBI
17	Chen B, Duan L, Yin G, Tan J and Jiang X: miR-381, a novel intrinsic WEE1 inhibitor, sensitizes renal cancer cells to 5-FU by up-regulation of Cdc2 activities in 786-O. J Chemother. 25:229–238. 2013. View Article : Google Scholar : PubMed/NCBI
18	Tang H, Wang Z, Liu Q, Liu X, Wu M and Li G: Disturbing miR-182 and −381 inhibits BRD7 transcription and glioma growth by directly targeting LRRC4. PLoS One. 9:e841462014. View Article : Google Scholar : PubMed/NCBI
19	Rothschild SI, Tschan MP, Jaggi R, Fey MF, Gugger M and Gautschi O: MicroRNA-381 represses ID1 and is deregulated in lung adenocarcinoma. J Thorac Oncol. 7:1069–1077. 2012. View Article : Google Scholar : PubMed/NCBI
20	Skalsky RL and Cullen BR: Reduced expression of brain-enriched microRNAs in glioblastomas permits targeted regulation of a cell death gene. PLoS One. 6:e242482011. View Article : Google Scholar : PubMed/NCBI
21	Martinez I, Gardiner AS, Board KF, Monzon FA, Edwards RP and Khan SA: Human papillomavirus type 16 reduces the expression of microRNA-381 in cervical carcinoma cells. Oncogene. 27:2575–2582. 2008. View Article : Google Scholar : PubMed/NCBI
22	Liao C, Wang J, Chen W, He D and Wang H: miR-381 regulates pituitary adenoma cell growth and migration by targeting TWIST1. Int J Clin Exp Pathol. 10:242–249. 2017.
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Sung CO, Lee KW, Han S and Kim SH: Twist1 is up-regulated in gastric cancer-associated fibroblasts with poor clinical outcomes. Am J Pathol. 179:1827–1838. 2011. View Article : Google Scholar : PubMed/NCBI
25	Qian J, Luo Y, Gu X, Zhan W and Wang X: Twist1 promotes gastric cancer cell proliferation through up-regulation of FoxM1. PLoS One. 8:e776252013. View Article : Google Scholar : PubMed/NCBI
26	Zhu X, Shen H, Yin X, Long L, Xie C, Liu Y, Hui L, Lin X, Fang Y, Cao Y, et al: miR-186 regulation of Twist1 and ovarian can-cer sensitivity to cisplatin. Oncogene. 35:323–332. 2016. View Article : Google Scholar : PubMed/NCBI
27	Yoshikawa T, Aoyama T, Tanabe K, Nishikawa K, Ito Y, Hayashi T, Cho H, Miyashita Y, Tsuburaya A and Sakamoto J: Feasibility and safety of transhiatal approach and D2 total gastrectomy after neoadjuvant chemotherapy for adenocarcinoma of the Esophago-gastric junction: A subset analysis of the COMPASS trial. Dig Surg. 33:424–430. 2016. View Article : Google Scholar : PubMed/NCBI
28	Burkitt MD, Varro A and Pritchard DM: Importance of gastrin in the pathogenesis and treatment of gastric tumors. World J Gastroenterol. 15:1–16. 2009. View Article : Google Scholar : PubMed/NCBI
29	Nielsen CB, Shomron N, Sandberg R, Hornstein E, Kitzman J and Burge CB: Determinants of targeting by endogenous and exogenous microRNAs and siRNAs. RNA. 13:1894–1910. 2007. View Article : Google Scholar : PubMed/NCBI
30	Jazdzewski K, Boguslawska J, Jendrzejewski J, Liyanarachchi S, Pachucki J, Wardyn KA, Nauman A and de la Chapelle A: Thyroid hormone receptor beta (THRB) is a major target gene for microRNAs deregulated in papillary thyroid carcinoma (PTC). J Clin Endocrinol Metab. 96:E546–E553. 2011. View Article : Google Scholar : PubMed/NCBI
31	Bourgeois P, Stoetzel C, Bolcato-Bellemin AL, Mattei MG and Perrin-Schmitt F: The human H-twist gene is located at 7p21 and encodes a B-HLH protein that is 96% similar to its murine M-twist counterpart. Mamm Genome. 7:915–917. 1996. View Article : Google Scholar : PubMed/NCBI
32	Li L and Wu D: miR-32 inhibits proliferation, epithelial-mesenchymal transition, and metastasis by targeting TWIST1 in non-small-cell lung cancer cells. Onco Targets Ther. 9:1489–1498. 2016. View Article : Google Scholar : PubMed/NCBI
33	Bing L, Hong C, Li-Xin S and Wei G: MicroRNA-543 suppresses endometrial cancer oncogenicity via targeting FAK and TWIST1 expression. Arch Gynecol Obstet. 290:533–541. 2014. View Article : Google Scholar : PubMed/NCBI
34	Li LZ, Zhang CZ, Liu LL, Yi C, Lu SX, Zhou X, Zhang ZJ, Peng YH, Yang YZ and Yun JP: miR-720 inhibits tumor invasion and migration in breast cancer by targeting TWIST1. Carcinogenesis. 35:469–478. 2014. View Article : Google Scholar : PubMed/NCBI
35	Sakamoto A, Akiyama Y, Shimada S, Zhu WG, Yuasa Y and Tanaka S: DNA methylation in the Exon 1 region and complex regulation of Twist1 expression in gastric cancer cells. PLoS One. 10:e01456302015. View Article : Google Scholar : PubMed/NCBI
36	Yuan W, Li T, Mo X, Wang X, Liu B, Wang W, Su Y, Xu L and Han W: Knockdown of CMTM3 promotes metastasis of gastric cancer via the STAT3/Twist1/EMT signaling pathway. Oncotarget. 7:29507–29519. 2016. View Article : Google Scholar : PubMed/NCBI